Current Studies
Rochester Victory Alliance is enrolling for HVTN-sponsored HIV studies, and is taking part in HVTN’s COVID-19 research to help find effective treatments, as well.
Below is a listing of our current and upcoming studies, along with study enrollment criteria.
Current HIV Vaccine Studies
HVTN 144
now screening
(ClinicalTrials.gov link: NCT06033209)
This is a Phase 1 study of an investigational vaccine and an adjuvant (a compound added to heighten immune response). The study vaccine includes a man-made protein that looks like a protein found on the outside of HIV.
Study vaccines used in this study are not made from live or killed HIV. These study vaccines cannot cause HIV infection or AIDS.
This study will enroll 84 participants who are in overall good health and between 18 and 55 years old. It will look at different doses of the study products and different ways of giving the products and different routes of giving the injections to see how these factors change the immune response.
Eligibility criteria:
- HIV-negative;
- Between 18–55 years old;
- In good general health.
Contact us
HVTN 313– Fusion Peptide Vaccine Study
enrollment full
ClinicalTrials.gov link: NCT06332339
This study is investigating three vaccines. Two of the vaccines are protein vaccines made to resemble a piece of protein on the surface of HIV. The third vaccine is an intranasal vaccine, made using an adenovirus; adenoviruses e viruses that cause illnesses like the common cold.
Because adenoviruses can be contagious, household contacts of participants are also invited to join the study for follow-up. Household contacts must be over the age of 18 and not be immunocompromised.
Study vaccines used in this study are not made from live or killed HIV. These study vaccines cannot cause HIV infection or AIDS.
Eligibility criteria:
- HIV-negative;
- Between 18–55 years old;
- BMI < 40; and
- In good general health.
Contact us
Current COVID-19 Studies
COVID-19 Treatment for Outpatients: SCORPIO-HR
fully enrolled
(ClinicalTrials.gov link: NCT05305547)
This study evaluates an oral anti-viral COVID-19 treatment versus placebo for non-hospitalized people recently infected with COVID-19.
You may be eligible to participate if you:
- tested positive for Covid-19 in the past 3 days;
- are showing symptoms (such as coughing, shortness of breath, feeling feverish, fatigue, nausea, chills, headaches, or sore throat, among others); and
- are at least 18 years of age and in good general health
Contact us
More information on this study is available at www.treatcovidearlystudy.com.